Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
暂无分享,去创建一个
Jeffrey W. Clark | V. Miller | G. Frampton | M. Fakih | D. Ryan | Siraj M. Ali | D. Ting | L. Zou | D. Catenacci | A. Parikh | A. Schrock | J. Chao | R. Corcoran | Yuting He | S. Klempner | T. Hong | J. Ross | L. Zou
[1] S. Badiyan,et al. Immunotherapy and radiation therapy for gastrointestinal malignancies: hope or hype? , 2020, Translational gastroenterology and hepatology.
[2] G. Cerqueira,et al. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma , 2020, Journal for ImmunoTherapy of Cancer.
[3] E. Vasile,et al. Immune Checkpoint Inhibitors in Esophageal Cancers: Are We Finally Finding the Right Path in the Mist? , 2020, International journal of molecular sciences.
[4] Jingjing Liu,et al. Chemotherapy combined with bevacizumab for the treatment of advanced lung adenocarcinoma cancer harboring EGFR‐ANXA2, EGFR‐RAD51, ATR and BRCA2 mutations: A case report , 2019, Thoracic cancer.
[5] K. Behbakht,et al. Society of Gynecologic Oncology 2018 Annual Meeting on Women's Cancer: Meeting report. , 2018, Gynecologic oncology.
[6] M. Fakih,et al. Lower tumor mutational burden (TMB) and hepatic metastases may predict for lack of response to PD-1 blockade in MSI-H metastatic colorectal cancer (MCRC). , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] L. Su,et al. The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials , 2018, Cancer management and research.
[8] John L Marshall,et al. Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. , 2018, JCO precision oncology.
[9] Juanita Lopez,et al. Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies , 2018, Therapeutic advances in medical oncology.
[10] A. Jeyasekharan,et al. Biomarkers for Homologous Recombination Deficiency in Cancer , 2018, Journal of the National Cancer Institute.
[11] A. Tan,et al. TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial. , 2018 .
[12] E. Swisher,et al. TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort. , 2018 .
[13] G. Mills,et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade , 2018, Nature Medicine.
[14] Michael T. Zimmermann,et al. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas , 2018, Cell reports.
[15] K. Mouw,et al. From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation , 2018, British Journal of Cancer.
[16] A. Maitra,et al. Phase II study of olaparib for BRCAness phenotype in pancreatic cancer. , 2018 .
[17] C. Iacobuzio-Donahue,et al. Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations , 2018, Clinical Cancer Research.
[18] Juanita Lopez,et al. Combining DNA damaging therapeutics with immunotherapy: more haste, less speed , 2017, British Journal of Cancer.
[19] James X. Sun,et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.
[20] Masaya Suenaga,et al. Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Nicolai J. Birkbak,et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. , 2017, The Lancet. Oncology.
[22] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[23] Michael S. Goldberg,et al. DNA Damage and Repair Biomarkers of Immunotherapy Response. , 2017, Cancer discovery.
[24] E. Kohn,et al. Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Levi Garraway,et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.
[26] P. Meltzer,et al. A phase II study of the anti-programmed death ligand-1 antibody durvalumab (D; MEDI4736) in combination with PARP inhibitor, olaparib (O), in metastatic castration-resistant prostate cancer (mCRPC). , 2017 .
[27] G. Hortobagyi,et al. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression , 2017, Clinical Cancer Research.
[28] J. Sosman,et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2017, Cell.
[29] L. Zou,et al. Functions, Regulation, and Therapeutic Implications of the ATR Checkpoint Pathway. , 2016, Annual review of genetics.
[30] J. Cleland,et al. Structured telephone support or non-invasive telemonitoring for patients with heart failure , 2016, Heart.
[31] Ignace Vergote,et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.
[32] Yu Shyr,et al. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade , 2016, Cancer Immunology Research.
[33] Zhijian J. Chen,et al. Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing , 2016, Nature Immunology.
[34] James X. Sun,et al. Evaluation of microsatellite instability (MSI) status in 11,573 diverse solid tumors using comprehensive genomic profiling (CGP). , 2016 .
[35] R. Bourgon,et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.
[36] Jason Kaplan,et al. Genomic landscape of DNA repair genes in cancer , 2016, Oncotarget.
[37] Lauren L. Ritterhouse,et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer , 2016, Oncotarget.
[38] J. Potash,et al. Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. , 2016, Cancer discovery.
[39] Michael S. Goldberg,et al. The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer. , 2015, Biochemical and biophysical research communications.
[40] P. Gimotty,et al. CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer , 2015, Cancer Immunology Research.
[41] A. Klein,et al. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma , 2015, Cancer Chemotherapy and Pharmacology.
[42] J. Kench,et al. Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.
[43] R. Gershoni-baruch,et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers , 2014, British Journal of Cancer.
[44] Alex M. Fichtenholtz,et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.
[45] Patrick J O'Connor,et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. , 2013, JAMA.
[46] Nicola J. Curtin,et al. DNA repair dysregulation from cancer driver to therapeutic target , 2012, Nature Reviews Cancer.
[47] Yuchen Jiao,et al. ATM mutations in patients with hereditary pancreatic cancer. , 2012, Cancer discovery.
[48] J. Hoeijmakers. Genome maintenance mechanisms for preventing cancer , 2001, Nature.